Print    Email
Decrease (-) Restore Default Increase (+)

Clinical Trials

IRB Number   11012
Treatment   Prostate Cancer
Trial Title   RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Description of Research  

The purpose of this study is to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the whole pelvic body area on you and your prostate cancer to find out which is better.

Principal Investigator   Jedidiah Monson, M.D.

Patients who are most likely to benefit from androgen deprivation therapy and whole-pelvic radiotherapy, defined as having a significant risk of lymph node involvement (e.g. >15%, based on the Roach formula) and being in one of the following risk groups:

• GS 7-10 + T1c-T2b (palpation) + PSA < 50 ng/ml (includes intermediate and high risk patients);
• GS 6 + T2c-T4 (palpation) or > 50% biopsies + PSA < 50 ng/ml;
• GS 6 + T1c-T2b (palpation) + PSA > 20 ng/ml.

Status   Open
Contact Name   Christyn Anderson, CCRC
Phone   (559) 450-7723
©  2015 

Saint Agnes Medical Center | 1303 E. Herndon Ave. Fresno, CA 93720 | 559-450-3000